Cohance Lifesciences Receives MCA Approval for Umang Vohra as Chairman and Group CEO
Cohance Lifesciences Ltd 路 Others (Uncategorized) 路 13 Oct 2026, 1:21 am
Cohance Lifesciences Receives MCA Approval for Umang Vohra as Chairman and Group CEO Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) received Central Government approval from the Ministry of Corporate Affairs on 12th Oct'26 (via letter dated 8th Oct'26) for the appointment of Mr. Umang Vohra as Chairman and Group CEO. This regulatory clearance follows the company's prior intimations dated 27th Apr'26 and 26th Jun'26, formalizing the top leadership transition.
Original exchange filing (PDF)
More announcements from Cohance Lifesciences Ltd
- The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property and Equity Holdings .... 路 12 Nov 2026
- The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasub Property Holdings LLP & Others 路 12 Nov 2026
- Investors Meet 路 11 Nov 2026
- Transcript of Con call 路 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasub Property Holdings LLP & Others 路 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property and Equity Holdings Pvt Ltd & Others 路 11 Nov 2026
- Investor Presentation 路 07 Nov 2026
- Update on USFDA inspection at Pashamylaram Manufacturing facility. 路 07 Nov 2026
